It is also possible that ARC neurons that do not express GLP-1R but do regulate feeding behavior, including AgRP neurons, may play a role in GLP-1RAinduced weight loss through indirect downstream circuit effects
Common eligibility criteria may include: BMI of 30 or higher BMI of 27 or higher with at least one weight-related health condition History of failed diet attempts or weight regain Appetite, cravings, or portion control challenges Metabolic risk factors such as insulin resistance, elevated glucose, high cholesterol, or hypertension Need for physician-supervised weight loss due to medical complexity Eligibility must be determined through a medical consultation
Warning signs include dark urine, reduced urine output, dizziness, confusion, or inability to keep down fluids for more than 24 hours
The article says naltrexone blocks opioid receptors in the hypothalamus, removing inhibition of pro-opiomelanocortin neurons that regulate satiety, while bupropion is a norepinephrine-dopamine reuptake inhibitor that increases alertness and reduces appetite by raising dopamine and norepinephrine in the brain's appetite-control centres
Nilsson K, Giovanella BC, Stehlin JS, Klein G
Supplier quality can vary significantly
